Testing a new drug combination for hard-to-treat Hodgkin lymphoma

Plain-English translation of NCT06393361 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a combination of three medications—chidamide, decitabine, and an anti-PD-1 antibody—can help people with Hodgkin lymphoma whose disease has stopped responding to previous treatments. You would receive either this new three-drug combination or the current standard two-drug combination (brentuximab vedotin plus anti-PD-1 antibody). The study will compare which treatment works better and is safer.

Hodgkin lymphoma that comes back or doesn't respond to earlier treatments is very hard to treat, and the outlook is especially poor for patients who cannot have a stem cell transplant or choose not to. This trial exists because early observations suggest that adding chidamide and decitabine to the anti-PD-1 antibody may be more effective than the current standard treatment.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with classical Hodgkin lymphoma that has been confirmed by a biopsy
your lymphoma has stopped responding to treatment or has come back after at least two previous treatment attempts
you are either not eligible for stem cell transplant or have chosen to refuse transplant
you are in good enough overall health to tolerate treatment (ECOG performance status less than 2)
your cancer has at least one measurable area larger than 1 centimeter

You likely don't qualify if…

you have already received chidamide, decitabine, and an anti-PD-1 antibody together, or brentuximab vedotin with an anti-PD-1 antibody
you have an autoimmune disease or have needed steroids or immunosuppressive medications for any condition
you have a serious uncontrolled medical condition or an active infection, especially a lung infection
you are pregnant, breastfeeding, or plan to become pregnant during the trial
you have had an organ transplant from another person

What participation looks like

You would be randomly assigned to receive either the new three-drug combination (chidamide, decitabine, and anti-PD-1 antibody) or the current standard two-drug combination (brentuximab vedotin and anti-PD-1 antibody). The treatment would be given on a regular schedule, and you would have regular follow-up visits to check how well the medication is working and monitor for any side effects. The main goal is to see if the new combination helps your cancer stay under control longer than the standard treatment.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

China

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing